ARS Pharmaceuticals Analyst Ratings
ARS Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/21/2023 | 71.23% | Wedbush | $15 → $5 | Maintains | Outperform |
| 09/20/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 08/14/2023 | 413.7% | Wedbush | → $15 | Reiterates | Outperform → Outperform |
| 06/21/2023 | 413.7% | Wedbush | $17 → $15 | Maintains | Outperform |
| 05/18/2023 | 482.19% | Wedbush | → $17 | Reiterates | Outperform → Outperform |
| 05/12/2023 | 482.19% | Wedbush | → $17 | Reiterates | Outperform → Outperform |
| 05/10/2023 | 482.19% | Wedbush | → $17 | Reiterates | → Outperform |
| 01/31/2023 | 242.47% | Wedbush | → $10 | Initiates Coverage On | → Outperform |
| 01/04/2023 | — | William Blair | Initiates Coverage On | → Outperform | |
| 12/13/2022 | 379.45% | SVB Leerink | → $14 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 09/21/2023 | 71.23% | Wedbush | 15 美元 → 5 美元 | 維護 | 跑贏大盤 |
| 09/20/2023 | — | 威廉布萊爾 | 降級 | 跑贏大盤 → 市場表現 | |
| 08/14/2023 | 413.7% | Wedbush | → 15 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
| 06/21/2023 | 413.7% | Wedbush | 17 美元 → 15 美元 | 維護 | 跑贏大盤 |
| 05/18/2023 | 482.19% | Wedbush | → 17 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
| 05/12/2023 | 482.19% | Wedbush | → 17 美元 | 重申 | 跑贏大盤 → 跑贏大盤 |
| 05/10/2023 | 482.19% | Wedbush | → 17 美元 | 重申 | → 跑贏大盤 |
| 01/31/2023 | 242.47% | Wedbush | → 10 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
| 2023 年 4 月 1 日 | — | 威廉布萊爾 | 啓動覆蓋範圍開啓 | → 跑贏大盤 | |
| 12/13/2022 | 379.45% | SVB Leerink | → 14 美元 | 啓動覆蓋範圍開啓 | → 跑贏大盤 |
What is the target price for ARS Pharmaceuticals (SPRY)?
ARS Pharmicals（SPRY）的目標價格是多少？
The latest price target for ARS Pharmaceuticals (NASDAQ: SPRY) was reported by Wedbush on September 21, 2023. The analyst firm set a price target for $5.00 expecting SPRY to rise to within 12 months (a possible 71.23% upside). 10 analyst firms have reported ratings in the last year.
Wedbush於2023年9月21日公佈了ARS Pharmicals（納斯達克股票代碼：SPRY）的最新目標股價。該分析公司將目標股價定爲5.00美元，預計SPRY將在12個月內上漲至71.23％（可能上漲71.23％）。去年有10家分析公司公佈了評級。
What is the most recent analyst rating for ARS Pharmaceuticals (SPRY)?
ARS Pharmicals（SPRY）的最新分析師評級是多少？
The latest analyst rating for ARS Pharmaceuticals (NASDAQ: SPRY) was provided by Wedbush, and ARS Pharmaceuticals maintained their outperform rating.
ARS Pharmicals（納斯達克股票代碼：SPRY）的最新分析師評級由Wedbush提供，ARS Pharmicals維持其跑贏大盤評級。
When is the next analyst rating going to be posted or updated for ARS Pharmaceuticals (SPRY)?
ARS Pharmicals（SPRY）的下一次分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ARS Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ARS Pharmaceuticals was filed on September 21, 2023 so you should expect the next rating to be made available sometime around September 21, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與ARS Pharmicals的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。ARS Pharmicals的最後一次評級是在2023年9月21日提交的，因此你應該預計下一個評級將在2024年9月21日左右公佈。
Is the Analyst Rating ARS Pharmaceuticals (SPRY) correct?
分析師對ARS Pharmicals（SPRY）的評級是否正確？
While ratings are subjective and will change, the latest ARS Pharmaceuticals (SPRY) rating was a maintained with a price target of $15.00 to $5.00. The current price ARS Pharmaceuticals (SPRY) is trading at is $2.92, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的ARS Pharmicals（SPRY）評級保持不變，目標股價爲15.00美元至5.00美元。ARS Pharmicals（SPRY）的當前交易價格爲2.92美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。